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Abstract
Background: The aim of the present study was to evaluate the association between the histology of active and
chronic lesions and urinary protein and serum creatinine (SCr) levels, as common clinical endpoints in clinical trials
for lupus nephritis (LN).
Methods: In total, 119 patients diagnosed with LN class III, IV, and V, as defined by the International Society
of Nephrology/Renal Pathology Society, between 1990 and 2015, were enrolled in the present study. Multiple
regression analysis was performed to explore semi-quantitative histological variables associated with urinary
protein and SCr levels.
Results: The mean age of the enrolled patients was 45 years, and 79% were female. The mean SCr and
mean urinary protein levels at the time of renal biopsy were 0.87 mg/dl and 3.00 g/gCr, respectively. Class IV
(71%) was the most common type of LN followed by class III (17%), and class V (13%). Multicollinearity was
confirmed between monocellular infiltration (variance inflation factor [VIF] = 10.22) and interstitial fibrosis
(VIF = 10.29), and between karyorrhexis (VIF = 4.14) and fibrinoid necrosis (VIF = 4.29). Fibrinoid necrosis and
monocellular infiltration were subsequently excluded, and multiple regression analysis revealed that only the
urinary protein level was correlated with wire loop lesions (β-coefficient [β]: 1.09 and confidence interval [CI]:
0.35 to 1.83), and that the SCr level was correlated with glomerular sclerosis (β: 1.08 and CI: 0.43 to 1.74).
Conclusion: As urinary protein and SCr levels were not quantitatively associated with active lesions, they
may not accurately reflect the response to remission induction therapy in patients with LN.
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Background
While clinical trials for promising therapeutic agents for
lupus nephritis (LN), such as B cell targeted therapy,
cytokine-targeted therapy (IL-6 and IFN-a), and cyto-
toxic T lymphocyte-associated antigen 4, have been con-
ducted, none have shown improved outcomes compared
with controls [1]. These failures may be attributed to in-
adequate inclusion criteria, study populations, sample
sizes, and study duration [1, 2]. Furthermore, one study
focused on the definition of outcome measurements [3,
4].
Proteinuria and serum creatinine (SCr) have been con-
sidered as promising predictors for renal prognosis in
patients with LN [5–8]. Consequently, the primary out-
come of the majority of clinical studies for LN is defined
by urinary protein and SCr levels [9, 10]. Previous stud-
ies have revealed that measures of chronic lesions in LN,
such as the chronic index, glomerular sclerosis, and
interstitial fibrosis, are related to a poor renal outcome
[11, 12]. The estimated glomerular filtration rate (eGFR)
is calculated using the SCr level, and eGFR and protein-
uria are biomarkers for the classification of chronic kid-
ney disease [13]. Therefore, proteinuria and the SCr
level at renal biopsy may reflect chronic but not active
lesions, which may respond to immunosuppressive treat-
ment, and may serve as prognostic predictors for LN.
The main objective of this study was to explore the
histology of active and chronic lesions, as well as their
association with proteinuria and SCr level, in patients
with LN.
Methods
Study design, setting, and population
We retrospectively reviewed patients with LN at Okayama
University Hospital. Data from 1990 to 2006 and 2007–
2015 were collected from paper- and electronic-based re-
cords, respectively. Data collection was completed in
2016–2017. The enrolled patients fulfilled the 1997
American College of Rheumatology revised criteria for the
classification of systemic lupus erythematosus (SLE) [14].
Patients were eligible for participation in this study if they
had a histologically confirmed diagnosis of LN (class III,
IV, or V) according to the International Society of Neph-
rology/Renal Pathology Society (ISN/RPS) classification
[15]. Eligible patients were followed up from their first
renal biopsy for 10 years, until December 2015.
Clinical parameters
The following information was collected at the time
of the renal biopsy, prior to treatment: age, sex, SLE
disease activity index 2000, daily maximum dose of
prednisolone, use of immunosuppressants, SCr and
eGFR levels, urinary protein levels (g/gCr), hematuria
(dipstick test > 2+ and > 5 erythrocytes per high power
field), and active urine sediments. The eGFR was
evaluated by the equation developed by the Japanese
Society of Nephrology [16].
Histological parameters
For all participants, the histology of the first renal biopsy
sample was classified according to the ISN/RPS classifi-
cation by experienced nephrologists and/or pathologists.
Active glomerular lesions were defined by the presence
of endocapillary hypercellularity, leukocyte infiltration,
subendothelial hyaline deposits, interstitial inflammation,
karyorrhexis, fibrinoid necrosis, and cellular crescent
formation. Active interstitial lesions were defined by
monocellular infiltration. Chronic glomerular lesions
were defined by glomerular sclerosis, fibrosis adhesion,
and fibrous crescent formation, whereas chronic intersti-
tial lesions were defined by interstitial fibrosis. Arterio-
sclerosis was also defined by chronic lesions. Each renal
biopsy sample was processed using light and immuno-
fluorescence microscopy with standard methods of fix-
ation and staining. For semi-quantitative analysis, the
histological score was calculated as described in our pre-
vious study [17], where histological score = (0.5 × num-
ber of glomeruli with segmental lesions + 1 × number of
glomeruli with global lesions)/total number of glomeruli.
Interstitial lesions such as interstitial fibrosis, arterio-
sclerosis, and monocellular infiltration to interstitial,
tubular, and vascular lesions were semi-quantitatively
graded on a scale of 0, 1, 2, and 3 (absent, mild, moder-
ate, and severe, respectively). Interstitial lesions were cat-
egorized as high- or low-grade according to a cutoff
score of 2.
Outcomes
The primary outcome measures were the urinary protein
and SCr levels. The secondary outcome measure was the
cumulative 10-year renal survival rates from the date of
the renal biopsy. The renal endpoint was defined as >
40% decline in the eGFR.
Statistical analysis
Statistical analyses were performed using JMP® 14 soft-
ware (SAS Institute Inc., Cary, NC, USA) and STATA
v15 (StataCorp, College Station, TX, USA). All statistical
tests were 2-sided. p < 0 .05 was considered to indicate a
statistically significant difference. Complete case analyses
were performed, excluding patients with missing clinical
data at the time of the first biopsy. The descriptive sta-
tistics are expressed as the mean and standard deviation
(SD) for continuous variables, and as n (%) for categor-
ical variables. The cumulative renal survival rates were
calculated using Kaplan-Meier analysis. We censored pa-
tients that did not reach the renal endpoint when they
completed the 10-year follow-up or at the date of the
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last recorded visit until December 31, 2015. We calcu-
lated the number of patients at risk for reaching the end-
point from the date of the renal biopsy. Patients were
grouped according to urinary protein levels and the
eGFR, and survival rates were assessed using log-rank
tests.
Subsequently, multiple linear regression (ordinary least
squares regression) analysis was performed to explore
whether the histological findings contributed to urinary
protein and SCr levels. The primary dependent variables
were urinary protein and SCr levels at the time of renal
biopsy, which were recorded as continuous variables,
and the candidate variable was the renal histological
score. Urinary protein levels were log-transformed to
fulfill the assumption of a normal distribution of the re-
siduals. To address multicollinearity, which was assessed
using the variance inflation factor (VIF) [18, 19], we ana-
lyzed our data as two separate models excluding highly
correlated covariates. We performed multiple linear re-
gression analysis including age and sex for sensitivity
analysis.
Results
Patient characteristics at renal biopsy
From a total of 158 patients with LN, 119 patients with
ISN/RPS class III, IV, and/or V were enrolled in the
present study after eliminating 11 patients with class I,
II, or VI; 20 patients with a lack of clinical data; and
eight patients who underwent a re-biopsy. Patient char-
acteristics are shown in Table 1. The mean age of the
patients was 45 years, and 79% were female. The mean
SCr level and eGFR were 0.87 mg/dl and 77.3 ml/min/
m2, respectively, at the time of the first renal biopsy. The
mean urinary protein level was 3.00 g/gCr. Forty-six
(39%) patients were treated with prednisolone alone and
the others were treated with concomitant immunosup-
pressants for remission induction. Renal histology re-
vealed that class IV (71%) was the most common type,
followed by class III (17%) and class V (13%). The mean
(SD) scores of each histological lesion were as follows:
endocapillary proliferation, 0.26 (0.30); karyorrhexis, 0.06
(0.12); fibrinoid necrosis, 0.08 (0.14); rupture of the
glomerular basement membranes, 0.01 (0.03); extracapil-
lary proliferation, 0.05 (0.10); wire loop lesions, 0.14
(0.27); hyaline deposits, 0.02 (0.06); membranous lesions,
0.11 (0.28); glomerular sclerosis, 0.11 (0.16); fibrous ad-
hesions, 0.04 (0.07); and fibrous crescents, 0.01 (0.04).
The proportions of monocellular infiltration, interstitial
fibrosis, and arteriosclerosis with histological grade ≥ 2
were 43 (36%), 41 (34%), and 23 (19%), respectively. The
Pearson’s correlation coefficient for each histological le-
sion is presented in Supplementary Table 1.
During the mean observation period of 1931 days, 11
(9.2%) patients experienced a > 40% decrease in eGFR.
There was no significant difference in the renal 10-year
survival rate among the patients divided into four cat-
egories of urinary protein levels (Fig. 1 (a): log-rank test,
p = 0.37). Similarly, the renal survival rate did not differ
among patients stratified by SCr levels (Fig. 1 (b): log-
rank test, p = 0.88).
Explanatory histological variables for urinary protein
levels (log-transformed)
Multiple regression analysis was used to explore the ex-
planatory variables related to urinary protein levels
(Table 2, Model 1, mean VIF = 3.08). Wire loop lesions
emerged as an independent explanatory variable (β-coef-
ficient [β]: 1.08 and 95% confidence interval [CI]: 0.33 to
1.82). Multicollinearity was confirmed between monocel-
lular infiltration (VIF = 10.22) and interstitial fibrosis
(VIF = 10.29), and between karyorrhexis (VIF = 4.14) and
fibrinoid necrosis (VIF = 4.29). Therefore, fibrinoid ne-
crosis and monocellular infiltration were excluded from
subsequent multiple regression analysis (Table 2, Model
Table 1 Patient characteristics at renal biopsy
Characteristic Total Missing
n = 119 (%)
Age, years 45 (±16) –
Sex, female, n (%) 94 (79) –
Observation period, days 2958 (±2584) –
SLEDAI-2 K score 16 (±6) 53.8
ISN/RPS classification
Class III, n (%) 20 (17) –
Class III + V, n (%) 2 (10) –
Class IV, n (%) 84 (71) –
Class IV + V, n (%) 7 (8) 0.8
Class V, n (%) 15 (13) –




PSL alone, n (%) 46 (39)
Cyclophosphamide, n (%) 31 (26) –
Tacrolimus or cyclosporine, n (%) 22 (19) –
Mycophenolate mofetil, n (%) 13 (11) –
Others, n (%) 2 (2) –
Serum creatinine, mg/dl 0.87 (±0.51) –
eGFR, ml/min/m2 77.3 (±31.0) –
Urinary protein, g/gCr 3.00 (±2.78) –
Hematuria (scale > 2+), n (%) 52 (44) 2.5
Active urinary sediment, n (%) 77 (65) 4.2
Data are presented as the mean and standard deviation in brackets. SLEDAI-2 K
Systemic Lupus Erythematosus Disease Activity Index 2000; ISN/RPS
International Society of Nephrology/Renal Pathology Society; PSL Prednisolone;
eGFR Estimated glomerular filtration rate
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2, mean VIF = 1.40). In Model 2, wire loop lesions (β:
1.09 and 95% CI: 0.35 to 1.83) were also detected as an
independent explanatory variable for proteinuria. When
fibrinoid necrosis and interstitial fibrosis were excluded
from the analysis in Model 3, wire loop lesions (β: 1.00
and 95% CI: 0.28 to 1.71) were still detected as an inde-
pendent explanatory variable (Table 2, Model 3, mean
VIF = 1.40). Sensitivity analysis including age and sex
showed that only wire loop lesions were significantly re-
lated to proteinuria (β: 1.10 and 95% CI: 0.35 to 1.85 in
Model 2; β: 1.01 and 95% CI: 0.29 to 1.73 in Model 3)
(Supplementary Table 2).
Explanatory histological variables for serum creatinine
levels
Similarly to the analysis for urinary protein level, mul-
tiple regression analysis using all the histological vari-
ables was performed to explore the explanatory variables
related to the SCr level (Table 3, Model 1, Mean VIF =
3.08). Hyaline deposits (β: − 1.84 and 95% CI: − 3.64 to
− 0.04) and glomerular sclerosis (β: 1.10 and 95% CI:
0.43 to 1.76) emerged as independent explanatory vari-
ables in Model 1. After excluding fibrinoid necrosis and
monocellular infiltration in Model 2, and fibrinoid ne-
crosis and interstitial fibrosis in Model 3, glomerular
Fig. 1 Cumulative renal survival rate of the enrolled patients, stratified according to (a) urinary protein levels and (b) estimated glomerular
filtration rate (eGFR) at renal biopsy
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Table 2 Multiple regression analysis of log-transformed urinary protein levels at renal biopsy and histological variables
Variable Model 1 Model 2 Model 3
Coeff [95% CI] Coeff [95% CI] Coeff [95% CI]
Active lesions
Endocapillary proliferation 0.66 [− 0.12 to 1.44] 0.64 [− 0.13 to 1.41] 0.67 [− 0.10 to 1.43]
Karyorrhexis 0.93 [−2.11 to 3.97] 0.87 [− 1.14 to 2.87] 0.84 [− 1.16 to 2.83]
Fibrinoid necrosis −0.12 [− 2.82 to 2.58]
Rupture of glomerular basement membranes 2.34 [−5.52 to 10.21] 2.26 [−4.48 to 9.00] 2.14 [−4.60 to 8.87]
Extracapillary proliferation 1.79 [−0.63 to 4.22] 1.77 [−0.62 to 4.16] 1.84 [− 0.54 to 4.22]
Wire loop lesions 1.08 [0.33 to 1.82] 1.09 [0.35 to 1.83] 1.00 [0.28 to 1.71]
Hyaline deposits 1.18 [−2.65 to 5.00] 1.12 [−2.65 to 4.89] 1.39 [− 2.34 to 5.12]
Membranous lesions 0.64 [−0.07 to 1.35] 0.67 [− 0.02 to 1.35] 0.67 [− 0.01 to 1.36]
Monocellular infiltration
(category)
− 0.25 [− 1.48 to 0.98] − 0.07 [− 0.53 to 0.39]
Chronic lesions
Glomerular sclerosis 1.13 [− 0.28 to 2.54] 1.15 [− 0.24 to 2.54] 1.13 [− 0.24 to 2.49]
Fibrous adhesion − 0.40 [− 3.41 to 2.62] −0.35 [− 3.33 to 2.63] −0.25 [− 3.21 to 2.71]
Fibrous crescents 1.63 [− 3.93 to 7.19] 1.60 [− 3.76 to 6.95] 1.80 [− 3.56 to 7.15]
Interstitial fibrosis (category) 0.23 [− 1.01 to 1.47] 0.00 [− 0.47 to 0.47]
Arteriosclerosis (category) 0.15 [− 0.38 to 0.68] 0.13 [− 0.39 to 0.64] 0.17 [− 0.35 to 0.68]
Proteinuria was log-transformed to obtain a closer approximation to normal distribution. Covariates; Model 1: all independent explanatory variables; Model 2:
explanatory variables excluding fibrinoid necrosis and monocellular infiltration; Model 3: explanatory variables excluding fibrinoid necrosis and interstitial fibrosis.
Coeff β-Coefficient; CI Confidential interval
Table 3 Multiple regression analysis of serum creatinine levels at renal biopsy and histological variables
Variable Model 1 Model 2 Model 3
Coeff [95% CI] Coeff [95% CI] Coeff [95% CI]
Active lesions
Endocapillary proliferation 0.15 [− 0.22 to 0.51] 0.16 [− 0.20 to 0.52] 0.16 [− 0.2 to 0.52]
Karyorrhexis 0.08 [− 1.34 to 1.51] 0.20 [− 0.74 to 1.15] 0.23 [− 0.71 to 1.17]
Fibrinoid necrosis 0.18 [− 1.08 to 1.45]
Rupture of glomerular
basement membranes
0.16 [− 3.54 to 3.85] 0.34 [− 2.83 to 3.52] 0.39 [− 2.79 to 3.56]
Extracapillary proliferation 0.37 [− 0.77 to 1.51] 0.40 [− 0.73 to 1.52] 0.42 [− 0.7 to 1.54]
Wire loop lesions 0.13 [− 0.22 to 0.48] 0.12 [− 0.22 to 0.47] 0.08 [− 0.26 to 0.42]
Hyaline deposits −1.84 [− 3.64 to − 0.04] − 1.78 [− 3.56 to − 0.00] − 1.67 [− 3.43 to 0.09]
Membranous lesions −0.17 [− 0.50 to 0.17] −0.19 [− 0.51 to 0.13] −0.15 [− 0.48 to 0.17]
Monocellular infiltration (category) 0.22 [− 0.36 to 0.80] 0.26 [0.04 to 0.47]
Chronic lesions
Glomerular sclerosis 1.10 [0.43 to 1.76] 1.08 [0.43 to 1.74] 1.07 [0.43 to 1.72]
Fibrous adhesion 0.73 [−0.69 to 2.14] 0.68 [−0.72 to 2.08] 0.79 [− 0.61 to 2.19]
Fibrous crescents −1.30 [− 3.91 to 1.31] −1.31 [− 3.84 to 1.21] − 1.32 [− 3.84 to 1.21]
Interstitial fibrosis (category) 0.06 [− 0.52 to 0.65] 0.27 [0.05 to 0.49]
Arteriosclerosis (category) − 0.04 [− 0.29 to 0.21] −0.02 [− 0.26 to 0.23] − 0.02 [− 0.26 to 0.23]
Covariates; Model 1: all independent explanatory variables; Model 2: explanatory variables excluding fibrinoid necrosis and monocellular infiltration; Model 3:
explanatory variables excluding fibrinoid necrosis and interstitial fibrosis. Coeff β-Coefficient; CI Confidential interval
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sclerosis was still an independent explanatory variable
(Table 3, mean VIF = 1.40 in Model 2 and mean VIF =
1.40 in Model 3). Sensitivity analysis including age and
sex showed that glomerular sclerosis was a constant in-
dependent explanatory variable for SCr (β: 1.01 and 95%
CI: 0.37 to 1.66 in Model 2; β: 1.01 and 95% CI: 0.38 to
1.64 in Model 3) (Supplementary Table 3).
Discussion
In this study, we explored the associations between
histological findings and urinary protein and SCr levels
at renal biopsy. The urinary protein level was reflected
only in wire loop lesions, whereas the SCr level was only
correlated with glomerular sclerosis.
We could not confirm urinary protein and SCr levels
as predictive factors for the renal outcome of patients
with LN. As several previous reports showed that urin-
ary protein and SCr levels are the main predictors for
renal outcome [5–8], there is no doubt that they may
serve as predictors of renal prognosis. As the patients in
the present study had less severe disease and a shorter
observation period than previously reported, urinary
protein and SCr levels were unable to predict renal
prognosis in the present study.
Urinary protein level mainly reflected wire loop, but
not endocapillary or extracapillary, proliferative lesions
in our study. Our previous report showed that only
extracapillary proliferation was associated with poor
renal predictors in active lesion [17]. To the best of our
knowledge, the association between histological findings
and proteinuria has not been fully established in patients
with LN. Previous reports showed that the urinary pro-
tein level was related to the activity index [20, 21], while
another report showed that proteinuria was not corre-
lated with activity and chronicity indices [22]. A previous
study revealed that proteinuria was correlated with hya-
line deposition [12]. Considering these results, the appli-
cation of urinary protein levels as a biomarker of
treatment response for active LN may be challenging.
The SCr level was the only factor indicative of glom-
erular sclerosis in our study. This finding is supported
by previous studies showing that the SCr level mainly re-
flects chronicity in LN [12, 17, 22], and is correlated
with renal interstitial lesions, sclerotic glomeruli, and
tubular atrophy [23, 24]. Although the SCr level is a
promising biomarker for renal prognosis in patients with
LN, it was only associated with chronic lesions. There-
fore, the SCr level, similar to the urinary protein level,
may not be applicable as a biomarker of treatment re-
sponse in patients with LN with active lesions.
The present study had certain limitations. Firstly, this
is a cross-sectional study performed at renal biopsy;
therefore, we were unable to evaluate whether urinary
protein and SCr levels directly reflect the treatment
response of active lesions. However, we concluded that
SCr was unlikely to recover to a normal range if glom-
erular sclerosis was present. Secondly, we did not evalu-
ate treatment effects related to outcomes. Treatment
may be adjusted according to not only histological find-
ings, but also urinary protein and renal function. As our
patients exhibited a better renal outcome than previous
reports [6], we may have underestimated the predictive
power of proteinuria and renal function for renal
outcome.
Conclusions
The present study revealed that urinary protein and SCr
levels did not quantitatively reflect active lesions in LN.
Therefore, they may not be adequate biomarkers for
measuring the response to remission induction therapy
in patients with LN. Comparing the changes in candi-
date biomarkers and histological findings before and
after treatment may aid the identification of potential
biomarkers for monitoring the treatment response.
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